Jason T Hill

US Patent:

20120263707, Oct 18, 2012

Filed:

Jan 27, 2012

Appl. No.:

13/359755

Inventors:

Jason Hill - Chicago IL, US

Assignee:

Ligacept, LLC - Oak Brook IL

International Classification:

C07K 16/30
A61K 39/395
A61P 35/00
C12N 15/13

US Classification:

4241331, 5303873, 536 2353

Abstract:

Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB 1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of ErbB1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.

US Patent:

20150247135, Sep 3, 2015

Filed:

May 19, 2015

Appl. No.:

14/715710

Inventors:

Jason Hill - Chicago IL, US

Assignee:

LIGACEPT, LLC - Oak Brook IL

International Classification:

C12N 9/12

Abstract:

Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of Erb-B1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.

US Patent:

20150118228, Apr 30, 2015

Filed:

Apr 25, 2013

Appl. No.:

14/396965

Inventors:

- Oak Brook IL, US
Jason E. Hill - Chicago IL, US

International Classification:

C12N 9/12
C07K 14/71

US Classification:

4241341, 435194, 536 232, 4353201, 435361, 424 945, 435328

Abstract:

A chimeric ErbB ligand binding molecule is disclosed along with its pharmaceutically acceptable salt forms. The molecule is a protein that as part of its sequence includes the sequence of SEQ ID NOS: 1, 2, or 3. The molecule can be fused to an IgGFc and especially IgGFc containing cysteine to serine changes in the hinge region. For example, the fusion can be to IgG 1Fc DNA sequences that encode the binding molecules are also contemplated as well as vectors containing such DNA sequences and hosts that contain such vectors. Pharmaceutical compositions are contemplated that contain the binding molecule along with a pharmaceutically acceptable excipient.